49 related articles for article (PubMed ID: 31229682)
1. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.
Vorstman JA; Breetvelt EJ; Duijff SN; Eliez S; Schneider M; Jalbrzikowski M; Armando M; Vicari S; Shashi V; Hooper SR; Chow EW; Fung WL; Butcher NJ; Young DA; McDonald-McGinn DM; Vogels A; van Amelsvoort T; Gothelf D; Weinberger R; Weizman A; Klaassen PW; Koops S; Kates WR; Antshel KM; Simon TJ; Ousley OY; Swillen A; Gur RE; Bearden CE; Kahn RS; Bassett AS;
JAMA Psychiatry; 2015 Apr; 72(4):377-85. PubMed ID: 25715178
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome.
Mancini V; Maeder J; Bortolin K; Schneider M; Schaer M; Eliez S
Transl Psychiatry; 2021 May; 11(1):336. PubMed ID: 34052829
[TBL] [Abstract][Full Text] [Related]
3. Computer-vision analysis of craniofacial dysmorphology in 22q11.2 deletion syndrome and psychosis spectrum disorders.
Roalf DR; McDonald-McGinn DM; Jee J; Krall M; Crowley TB; Moberg PJ; Kohler C; Calkins ME; Crow AJD; Fleischer N; Gallagher RS; Gonzenbach V; Clark K; Gur RC; McClellan E; McGinn DE; Mordy A; Ruparel K; Turetsky BI; Shinohara RT; White L; Zackai E; Gur RE
J Neurodev Disord; 2024 Jun; 16(1):35. PubMed ID: 38918700
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial deficits in human iPSC-derived neurons from patients with 22q11.2 deletion syndrome and schizophrenia.
Li J; Ryan SK; Deboer E; Cook K; Fitzgerald S; Lachman HM; Wallace DC; Goldberg EM; Anderson SA
Transl Psychiatry; 2019 Nov; 9(1):302. PubMed ID: 31740674
[TBL] [Abstract][Full Text] [Related]
5. Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study.
Borgan F; Veronese M; Reis Marques T; Lythgoe DJ; Howes O
Eur Arch Psychiatry Clin Neurosci; 2021 Jun; 271(4):677-687. PubMed ID: 32986150
[TBL] [Abstract][Full Text] [Related]
6. Metyrosine treatment in a woman with chromosome 22q11.2 deletion syndrome and psychosis: a case study.
Engebretsen MH; Kildahl AN; Hoy IH; Bakken TL
Int J Dev Disabil; 2017 Nov; 65(2):116-121. PubMed ID: 34141331
[No Abstract] [Full Text] [Related]
7. Multinuclear Magnetic Resonance Spectroscopy at Ultra-High-Field: Assessing Human Cerebral Metabolism in Healthy and Diseased States.
Veeraiah P; Jansen JFA
Metabolites; 2023 Apr; 13(4):. PubMed ID: 37110235
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome.
Evers LJ; van Amelsvoort TA; Bakker JA; de Koning M; Drukker M; Curfs LM
Psychopharmacology (Berl); 2015 Sep; 232(18):3319-25. PubMed ID: 26055684
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal perspectives on the psychosis spectrum in 22q11.2 deletion syndrome.
Tang SX; Gur RE
Am J Med Genet A; 2018 Oct; 176(10):2192-2202. PubMed ID: 29048724
[TBL] [Abstract][Full Text] [Related]
10. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome.
Prasad SE; Howley S; Murphy KC
Dev Disabil Res Rev; 2008; 14(1):26-34. PubMed ID: 18636634
[TBL] [Abstract][Full Text] [Related]
11. Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case.
Vingerhoets C; Tse DHY; van Amelsvoort T
Eur J Med Genet; 2019 Aug; 62(8):103705. PubMed ID: 31229682
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.
Vingerhoets C; Tse DH; van Oudenaren M; Hernaus D; van Duin E; Zinkstok J; Ramaekers JG; Jansen JF; McAlonan G; van Amelsvoort T
J Psychopharmacol; 2020 Aug; 34(8):856-863. PubMed ID: 32448020
[TBL] [Abstract][Full Text] [Related]
13. The Relationships between Dopaminergic, Glutamatergic, and Cognitive Functioning in 22q11.2 Deletion Syndrome: A Cross-Sectional, Multimodal
van Hooijdonk CFM; Tse DHY; Roosenschoon J; Ceccarini J; Booij J; van Amelsvoort TAMJ; Vingerhoets C
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140839
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
